1．Crettola S，Petrovicb N，Murraya M．Pharmacogenetics of phaseⅠ and phaseⅡdrug metabolism current pharmaceutical design，2010，16，204-219

2．Evans WE，RellingMV．Pharmacogenomics：Translating Functional Genomics into Rational Therapeutics．Science，1999，286：487-491

3．Ginsburg GS，Willard HF．Genomic and personalized medicine：foundations and applications．Transl Res．2009；154：277-87

4．Hall IP，Pirmohamed M．Pharmacogenetics．New York：Taylor and Fracis Group，2006

5．Kalow W．Pharmacogenetics of Drug Metabolism．New York：Pergamon Press，1992

6．Weber WW．Pharmacogenetics．New York：OxfordUniversity Press，1997

7．Zhou HH．Racial differences in drug response：Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites．N Eng J Med 1989，320：565-570

8．Wadelius M，Sörlin K，Wallerman O，et al．Warfarin sensitivity related to CYP2C9，CYP3A5，ABCB1（MDR1）and other factors．The pharmacogenomics journal，2004，4（1）：40-48

9．Wadelius M，Chen LY，Downes K，et al．Common VKORC1 and GGCX polymorphisms associated with warfarin dose．The pharmacogenomics journal，2005，5（4）：262-270

10．Lindh JD，Holm L，Andersson ML，et al．Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis．European journal of clinical pharmacology，2009，65（4）：365-375

11．周宏灏．遗传药理学．北京：人民军医出版社，2003